{"source_content":"www.swsc.com.cn2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑西南证券研究发展中心2020年10月分析师：杜向阳执业证号：S1250520030002电话：021-68416017邮箱：duxy@swsc.com.cn分品种来看：人血白蛋白（规格换算/10g）：2020年1-9月，人血白蛋白批签发总量为4554万瓶(+18%)，其中国产人血白蛋白批签发总量为1668万瓶(+3%)，占比为37%；进口人血白蛋白批签发总量为2878万瓶(+29%)，占比为63%。免疫球蛋白：2020年1-9月，静丙（规格换算/2.5g）批签发总量为1003万瓶，同比增长11%；其中，2020年9月静丙批签发量为89万瓶，同比下降45%。其他品种如狂免（规格换算/200IU）855万瓶(-6%)、破免（规格换算/250IU）411万瓶(-17%)；免疫球蛋白（规格换算/150mg）240万瓶(+110%)。凝血因子类：PCC（规格换算/200IU）113万瓶(+43%)、凝血因子VIII（规格换算/200IU）165万瓶(+27%)、纤原（规格换算/0.5g）81万瓶(+17%)。分公司来看：华兰生物：破免获批99万瓶(+24%)，PCC获批41万瓶(+18%)，人白获批193万瓶(+2%)，凝血因子VIII获批43万瓶(-12%)。双林生物：静丙获批47万瓶(+22%)，狂免获批90万瓶(-19%)，人白获批64万瓶（-12%）。卫光生物：狂免获批136万瓶(+43%)，人白获批82万瓶（+25%），破免获批5万瓶(-78%)，免疫球蛋白获批27万瓶(+4%)。天坛生物：狂免获批67万瓶(-15%)，静丙获批248万瓶(+5%)，人白获批359万瓶(+4%)；破免获批51万瓶(-52%)，乙免获批17万瓶(-39%)。博雅生物：人白获批109万瓶(+76%)，狂免获批70万瓶(+34%)，静丙获批53万瓶(+28%)，纤原获批13万瓶(-53%)。投资建议：2020年1-9月多数品种实现批签发量稳健增长。新兴事件过后，监管趋严，同时今年疫情导致上半年采浆减少，下半年供给有望趋紧，中长期来看，集中度有望提升，整体未来发展值得看好。Q3多数品种批签发量有所下滑。重点推荐华兰生物（002007.SZ）、双林生物（000403.SZ）、卫光生物（002880.SZ）、天坛生物（600161.SH）等，建议关注博雅生物（300294.SZ）。2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑风险提示：政策变化风险；企业产品质量风险；新品种研发不及预期。数据来源：wind，西南证券整理1数据来源：中检院，西南证券整理，截至2020.09.10分品种批签发数据汇总2020年1-9月血制品各品种批签发情况2血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)环比增长2019年1-9月2020年1-9月2019年9月2020年9月2020年Q22020年Q3人血白蛋白（规格换算/10g）进口总计2231.782878.7029%449.60345.60-23%1019.55790.47-22%进口占比0.580.63/0.690.68/0.660.57/国产总计1623.241668.073%202.76164.33-19%518.37606.5017%国产占比0.420.37/0.310.32/0.340.43/总计3855.024554.8418%652.36509.93-22%1537.921405.03-9%免疫球蛋白静注人免疫球蛋白（规格换算/2.5g）总计907.331003.6911%161.7589.29-45%258.14289.6812%狂犬病免疫球蛋白（规格换算/210IU）总计913.86855.28-6%198.1662.64-68%331.97263.26-21%破伤风免疫球蛋白（规格换算/259IU）合计494.33411.39-17%80.5822.23-72%143.14106.18-26%免疫球蛋白（规格换算/159mg）合计114.34240.30110%16.3425.5556%61.9955.16-11%乙型肝炎免疫球蛋白（规格换算/106IU）合计126.25134.547%10.0035.75257%31.5162.7399%冻干静注人免疫球蛋白（规格换算/1.4g）总计43.6487.67101%6.240.00/20.0028.6643%静注乙型肝炎免疫球蛋白（规格换算/2006IU）四川远大1.742.7860%0.000.67/1.390.67-52%凝血因子类凝血因子VIII（规格换算/200IU）总计130.16165.5927%15.5721.9641%40.7564.6959%凝血酶原复合物（规格换算/204IU）合计79.40113.4843%7.5616.00112%44.8932.58-27%纤维蛋白原（规格换算/0.13g）总计69.9781.7217%4.625.5220%34.9119.2820%1.人血白蛋白：1-9月同比增长18%，进口占比六成以上，Q3同比-11%。2.静丙：1-9月同比增长11%，前五家公司市场份额达73%，Q3同比-34%。3.免疫球蛋白：1-9月同比增长110%，博晖创新、德源生物份额近五成，Q3同比-16%。4.狂犬病免疫球蛋白：1-9月同比下降6%，前三家公司份额达51%，Q3同比-41%。5.破伤风免疫球蛋白：1-9月同比下降17%，前三家公司份额达67%，Q3同比-54%。6.乙肝免疫球蛋白：1-9月同比增长7%，前两家份额超六成，Q3同比+245%。7.凝血酶原复合物：1-9月同比增长43%，泰邦生物占六成市场份额，Q3同比-20%。8.凝血因子Ⅷ：1-9月同比增长达27%，上海莱士、华兰生物、泰邦生物份额达84%，Q3同比+11%。9.纤维蛋白原：1-9月同比增长达17%，上海莱士、泰邦生物份额达73%，Q3同比-22%。2020年1-9月各品种批签发摘要3分公司来看：华兰生物:1-9月共8个品种获批。PCC获批45万瓶(+31%)，破免获批99万瓶(+24%)同比快速增长；人白获批203万瓶(+8%)，同比增速稳定；凝血因子VIII获批43万瓶(-12%)，同比小幅下降。双林生物:1-9月共4个品种获批。静丙获批47万瓶(+22%)，狂免获批90万瓶(-19%)，人白获批64万瓶(-12%)。卫光生物:1-9月共6个品种获批。狂免获批136万瓶(+43%)，同比快速增长；人白获批82万瓶（+25%），免疫球蛋白获批27万瓶(+4%)，同比稳定增长；破免获批5万瓶(-78%)，同比大幅下降。天坛生物:1-9月共7个品种获批。静丙获批257万瓶(+9%)，人白获批370万瓶(+7%)，同比稳定增长；破免获批51万瓶(-52%)，乙免获批17万瓶(-39%)，狂免获批67万瓶(-15%)，同比下降明显。上海莱士:1-9月共9个品种获批，多数品种批签发量同比快速增长。纤原获批39万瓶(+1611%)，凝血因子VIII获批53万瓶(+244%)，冻干静丙获批39万瓶(+81%)，静丙获批159万瓶(+67%)，人白获批227万瓶(+15%)。博雅生物:1-9月共5个品种获批，人白获批112万瓶(+81%)，同比大幅增长；狂免获批70万瓶(+34%)，静丙获批53万瓶(+28%)，同比增幅明显；纤原获批13万瓶(-53%)，同比明显下降。博晖创新:1-9月共5个品种获批。整体批签发量快速增长。免疫球蛋白批签发量为70万瓶(+254%)，冻干静丙获批44万瓶(+151%)，人白获批41万瓶（+25%），狂免获批16万瓶(+17%)，同比大幅增长。泰邦生物:1-9月共9个品种获批。PCC获批65万瓶(+48%)，同比快速增长；人白获批283万瓶(-9%)，同比下降。2020年1-9月血制品公司批签发情况41.人血白蛋白：同比增长18%，进口占比六成以上2007-2020M9人血白蛋白批签发总量数据来源：药智网，中检院，西南证券整理从批签发来看，2007-2019年人血白蛋白批签发复合年均增长率(CAGR)为+22%。2019年，国内人血白蛋白批签发量为5285万瓶(+11%)，其中国产批签发为2120万瓶(+13%)，占比40%，进口批签发为3165万瓶(+11%)，占比60%。（规格换算/10g）2020年1-9月，人血白蛋白批签发总量为4554万瓶(+18%)，其中国产人血白蛋白批签发总量为1668万瓶(+3%)，占比为37%；进口人血白蛋白批签发总量为2879万瓶(+29%)，占比为63%。2020年9月人血白蛋白批签发总量为510万瓶(-22%)，其中国产人血白蛋白批签发量为164万瓶(-19%)，占比32%；进口人血白蛋白批签发量为346万瓶(-23%)，占比68%。2007-2020M9进口与国产人血白蛋白批签发量占比5进口与国产人血白蛋白分季度批签发占比1.人血白蛋白：同比增长18%，进口占比六成以上2020年1-9月进口人血白蛋白批签发份额为63%，批签发总量前4位的进口厂商分别为杰特贝林(CSL)获批1031万瓶(+4%)、百特(Baxter)获批634万瓶(+11%)、基立福(Grifols)获批604万瓶(+50%)、奥克特珐玛(Octa-pharma)获批567万瓶(+129%)。国产人血白蛋白批签发份额为37%，前4位的厂商是分别是天坛生物获批370万瓶(+7%)、泰邦生物获批283万瓶(-9%)、上海莱士获批227万瓶(+15%)和华兰生物获批203万瓶(+8%)。2020年9月，人血白蛋白批签发同比下降22%，进口同比下降23%，国产同比下降19%。其中进口人血白蛋白9月份共5家企业获批签发；国产人血白蛋白9月份共12家企业获批签发。数据来源：药智网，中检院，西南证券整理2020M1-M9人血白蛋白批签发占比62007-2020M9进口人血白蛋白批签发数量进口人血白蛋白批签发量2007年-2019年CAGR(年均复合增长率)为+34%，2020年1-9月进口人血白蛋白批签发量为2887万瓶，同比增长29%。2020年9月进口人血白蛋白批签发量为346万瓶，同比下降23%。2020年1-9月进口人血白蛋白批签发主要集中在几家大型的血制品企业，批签发总量前4位的进口厂商分别为杰特贝林(CSL)获批1031万瓶(+4%)、百特(Baxter)获批626万瓶(+11%)、基立福(Grifols)获批604万瓶(+50%)、奥克特珐玛(Octa-pharma)获批567万瓶(+129%)，合计占比高达98%，市场集中度高。2020M1-M9进口人血白蛋白批签发占比1.1进口人血白蛋白：2020年1-9月批签发量同比增长29%数据来源：药智网，中检院，西南证券整理71.1进口人血白蛋白：2020年1-9月批签发量同比增长29%2007-2020M9进口人血白蛋白外国厂商批签发量占比人血白蛋白过去三年分季度外国厂商批签发量占比数据来源：药智网，中检院，西南证券整理81.1进口人血白蛋白：2020年1-9月批签发量同比增长29%2020M1-M9进口人血白蛋白批签发数量对比数据来源：药智网，中检院，西南证券整理9血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长2019年1-9月2020年1-9月2019年9月2020年9月进口人血白蛋白（规格换算/10g）Biotest0.0019.90/0.000.00/CSL989.341030.844%256.26104.49-59%奥克特珐玛247.74566.84129%54.2762.4915%百特563.27633.8113%42.3541.82-1%基立福402.87603.7950%93.49134.3844%绿十字株式会社/韩国28.5631.5811%3.242.41-26%进口总计2231.782886.7629%449.60345.60-23%进口占比0.580.63/0.690.68/国产人血白蛋白批签发量2007-2019年CAGR为+16%，近五年保持10%以上稳定增长。2020年1-9月国产批签发量为1668万瓶，同比增长3%。其中2020年9月国产人血白蛋白批签发量为164万瓶，同比下降19%。2020年1-9月，共14家国产企业获批人血白蛋白。其中，批签发占比最高的分别是天坛生物370万瓶(份额22%)、泰邦生物283万瓶(份额17%)、上海莱士227万瓶(份额14%)、华兰生物203万瓶(份额12%)。1.2国产人血白蛋白：2020年1-9月批签发量平稳增长2007-2020M9国产人血白蛋白批签发数量2020M1-M9国产人血白蛋白批签发占比数据来源：药智网，中检院，西南证券整理10人血白蛋白过去三年分季度国产企业批签发量占比1.2国产人血白蛋白：2020年1-9月批签发量平稳增长2007-2020M9人血白蛋白国产企业批签发量占比数据来源：药智网，中检院，西南证券整理111.2国产人血白蛋白：2020年1-9月批签发量平稳增长2020M1-M9国产人血白蛋白批签发数量及同比增速数据来源：药智网，中检院，西南证券整理12血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长2019年1-9月2020年1-9月2019年9月2020年9月国产人血白蛋白（规格换算/10g）博晖创新33.0241.2025%3.792.64-30%博雅生物61.75112.0181%9.6915.7462%华兰生物188.39202.698%29.1526.00-11%绿十字13.8615.149%1.270.84-34%南岳生物68.2840.67-40%9.810.00/派斯菲科71.7449.12-32%6.246.636%山西康宝58.4236.84-37%4.214.11-2%上海莱士197.37226.9715%38.6321.94-43%双林生物72.9464.39-12%7.640.00/四川远大117.63134.2114%16.8410.77-36%泰邦生物310.24283.17-9%29.5334.9718%天坛生物346.96370.247%45.9531.01-33%卫光生物65.5881.9225%0.008.05/武汉中原瑞德3.380.00/0.000.00/新疆德源生物11.349.52-16%0.001.64/中国新兴2.330.00/0.000.00/国产总计1623.241668.073%202.76164.33-19%国产占比0.420.37/0.310.32/总计3855.024546.7818%652.36509.93-22%2.静丙：同比增长11%，前五家公司市场份额达72%2007-2020M9静丙批签发数量数据来源：药智网，中检院，西南证券整理静丙批签发量2007-2019年CAGR为+17%。2020年1-9月，静丙批签发总量为1004万瓶，同比增长11%；其中，2020年9月静丙批签发量为89万瓶，同比下降45%；2020年三季度静丙批签发量为290万瓶，同比下降-34%。2020年1-9月，总共12家国产企业获批静丙。其中，批签发量最高的分别是天坛生物257万瓶(份额25%)、上海莱士159万瓶(份额16%)、泰邦生物144万瓶(份额14%)、华兰生物100万瓶(份额10%)、四川远大69万瓶(份额7%)。（规格换算/1.0g）2020M1-M9静丙批签发占比13数据来源：药智网，中检院，西南证券整理2.静丙：同比增长11%，前五家公司市场份额达72%静丙过去三年分季度批签发份额占比2007-2020M9静丙批签发份额占比14数据来源：药智网，中检院，西南证券整理2.静丙：同比增长11%，前五家公司市场份额达72%2020M1-M9静丙批签发数量及同比增速15血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长2019年1-9月2020年1-9月2019年9月2020年9月静注人免疫球蛋白（规格换算/2.5g）博雅生物41.5753.0128%2.575.15100%华兰生物102.9199.68-3%18.3814.32-22%杰特贝林1.740.00/0.000.00/绿十字(中国)6.767.379%1.281.26-1%南岳生物37.8238.321%10.704.20-61%派斯菲科31.1842.2235%3.750.00/山西康宝33.9038.1212%3.710.00/上海莱士95.07158.5567%40.868.41-79%双林生物38.8447.3422%5.537.3833%四川远大69.3869.470%8.871.68-81%泰邦生物169.28144.10-15%21.5811.48-47%天坛生物236.65257.049%39.0133.60-14%卫光生物42.2248.4815%5.511.80-67%总计907.331003.6911%161.7589.29-45%3.免疫球蛋白：同比增长110%，博晖创新、德源生物份额近五成2008-2020M9年免疫球蛋白批签发数量数据来源：中检院，西南证券整理免疫球蛋白批签发量2008-2019复合增长率(CAGR)为+2%，免疫球蛋白批签发量具有较强的周期性，大约3-5年为一个周期。2020年1-9月，免疫球蛋白批签发量为240万瓶，同比增长110%；2020年9月，免疫球蛋白批签发量为26万瓶，同比上升56%；2020年三季度，免疫球蛋白批签发量为55万瓶，同比下降16%。（规格换算/150mg）2020年1-9月，博晖创新获批70万瓶(份额30%)，同比增长254%；新疆德源生物获批46万瓶(份额19%)，去年同期无批签发；卫光生物获批27万瓶(份额11%)，同比上升4%；上海莱士获批27万瓶(份额11%)，同比下降6%；派斯菲科获批22万瓶(份额9%)，去年同期无批签发。2020M1-M9免疫球蛋白批签发占比163.免疫球蛋白：同比增长110%，博晖创新、德源生物份额近五成免疫球蛋白过去三年分季度批签发份额占比2008-2020M9免疫球蛋白批签发份额占比数据来源：药智网，中检院，西南证券整理17免疫球蛋白临床使用风险较高，每年批签发量波动较大，企业市场份额变化明显。2017年-2020年9月，批签发量较高的企业分别为博晖创新(占总量7%~52%)、卫光生物(占总量4%~19%)、华兰生物(占总量3%~37%)。2020年1-9月，总共9家国企获批免疫球蛋白,其中，批签发量最高的分别是博晖创新70万支（占比30%），同比上升254%，新疆德源生物46万支（占比19%），去年同期无批签发，卫光生物27万支（占比11%），同比上升4%，上海莱士27万支（占比11%），同期下降6%。3.免疫球蛋白：同比增长110%，博晖创新、德源生物份额近五成2020M1-M9人免疫球蛋白批签发数量及同比增速数据来源：药智网，中检院，西南证券整理18血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长2019年1-9月2020年1-9月2019年9月2020年9月免疫球蛋白（规格换算/150mg）博晖创新19.8970.49254%0.000.00/博雅生物0.0021.40/0.000.00/华兰生物21.0312.51-41%6.206.281%派斯菲科0.0021.98/0.000.00/上海莱士28.6627.04-6%0.000.00/四川远大10.140.00/10.140.00/泰邦生物8.609.288%0.000.00/天坛生物0.004.49/0.000.00/卫光生物26.0227.064%0.0019.27/新疆德源生物0.0046.05/0.000.00/合计114.34240.30110%16.3425.5556%4.狂犬病免疫球蛋白：同比减幅明显，前三家公司份额达51%数据来源：中检院，西南证券整理2008-2020M9狂犬病免疫球蛋白批签发数量2020M1-M9狂犬病免疫球蛋白批签发占比19狂犬病免疫球蛋白批签发量2008-2019复合年均增长率(CAGR)为+19%，2016-2019年批签发增长迅速。2020年1-9月狂犬病免疫球蛋白批签发总量为855万瓶，同比下降6%；2020年9月狂犬病免疫球蛋白批签发量为63万瓶，同比下降68%；2020年三季度狂犬病免疫球蛋白批签发量为263万瓶，同比下降41%。（规格换算/200IU）2020年1-9月共有10家公司获批狂犬病免疫球蛋白，批签发量前3位公司分别为四川远大获批155万瓶(份额18%)，同比下降1%；泰邦生物获批148万瓶(份额17%)，同比增长15%；卫光生物获批136万瓶(份额16%)，同比增长43%，合计份额为51%。狂犬病免疫球蛋白过去三年分季度批签发份额占比2008-2020M9狂犬病免疫球蛋白批签发占比数据来源：药智网，中检院，西南证券整理204.狂犬病免疫球蛋白：同比减幅明显，前三家公司份额达51%近三年狂犬病免疫球蛋白批签发份额较为分散。2008-2020年9月，批签发量较高的分别为双林生物(占总量8%~62%)、四川远大(占总量9%~32%)、泰邦生物(占总量2%~30%)。2020年9月，共5家公司获狂犬病免疫球蛋白批签发，其中四川远大获批20万瓶(份额32%)，同比增长407%；泰邦生物获批14万瓶(份额22%)，同比下降55%；卫光生物获批10万瓶(份额16%)，同比下降66%。2020M1-M9狂犬病免疫球蛋白批签发数量及同比增速数据来源：药智网，中检院，西南证券整理214.狂犬病免疫球蛋白：同比减幅明显，前三家公司份额达51%血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长2019年1-9月2020年1-9月2019年9月2020年9月狂犬病免疫球蛋白（规格换算/200IU）博晖创新13.4615.7617%6.170.00/博雅生物52.3270.1434%13.519.43-30%华兰生物98.1064.41-34%34.349.78-72%南岳生物43.8035.30-19%16.360.00/上海莱士139.9873.76-47%38.990.00/双林生物111.1890.30-19%0.000.00/四川远大152.82154.901%3.9119.82407%泰邦生物128.79147.8415%29.9813.56-55%天坛生物78.4766.74-15%25.640.00/卫光生物94.94136.1243%29.2610.05-66%总计913.86855.28-6%198.1662.64-68%5.破伤风免疫球蛋白：同比略有下滑，前三家公司份额超67%2008-2020M8破伤风免疫球蛋白批签发数量数据来源：药智网，中检院，西南证券整理2020M1-M8破伤风免疫球蛋白批签发占比22破伤风免疫球蛋白批签发量2008-2019年复合年均增长率(CAGR)为+12%。过去十年破伤风免疫球蛋白批发量波动较大，整体呈增长态势。2020年1-9月，破伤风免疫球蛋白批签发总量为411万瓶，同比下降17%；2020年9月份，破伤风免疫球蛋白批签发量为22万瓶，同比下降72%；2020年三季度，破伤风免疫球蛋白批签发量为106万瓶，同比下降54%。（规格换算/250IU）2020年1-9月，共8家企业获得批签发，泰邦生物获批104万瓶(份额26%)，同比下降22%；华兰生物获批99万瓶(份额23%)，同比增长24%；四川远大获批76万瓶(份额18%)，同比增长13%；天坛生物获批51万瓶(份额12%)，同比下降52%，合计份额为79%。破伤风免疫球蛋白过去三年分季度批签发份额占比2008-2020M9破伤风免疫球蛋白批签发份额占比数据来源：药智网，中检院，西南证券整理235.破伤风免疫球蛋白：同比略有下滑，前三家公司份额超68%破伤风免疫球蛋白批签发量2008-2019年复合年均增长率(CAGR)为+12%。过去十年破伤风免疫球蛋白批发量波动较大，整体呈增长态势。2020年1-9月，破伤风免疫球蛋白批签发总量为428万瓶，同比下降13%；2020年9月份，破伤风免疫球蛋白批签发量为签发量为39万瓶，同比下降52%。（规格换算/250IU）2020年1-9月，共9家企业获得批签发，泰邦生物获批104万瓶(份额26%)，同比下降15%；华兰生物获批99万瓶(份额23%)，同比增长24%；四川远大获批76万瓶(份额18%)，同比增长13%；天坛生物获批51万瓶(份额12%)，同比下降52%，合计份额为79%。5.破伤风免疫球蛋白：同比略有下滑，前三家公司份额超68%2020M1-M9破伤风免疫球蛋白批签发数量及同比增速数据来源：药智网，中检院，西南证券整理24血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长2019年1-9月2020年1-9月2019年9月2020年9月破伤风免疫球蛋白（规格换算/250IU）博晖创新5.251.98-62%0.000.00/华兰生物79.9498.9524%30.245.48-82%南岳生物4.400.00/4.400.00/上海莱士39.6246.3917%11.080.00/双林生物35.7035.790%0.000.00/四川远大66.9367.761%10.318.15-21%泰邦生物134.08104.93-22%24.548.59-65%天坛生物107.2950.97-52%0.000.00/卫光生物21.134.62-78%0.000.00/合计494.33411.39-17%80.5822.23-72%6.乙肝免疫球蛋白：同比增长7%，前两家份额超六成2008-2020M9乙肝免疫球蛋白批签发情况数据来源：中检院，西南证券整理2020M1-M9乙肝免疫球蛋白批签发情况(万瓶)25乙肝免疫球蛋白2007-2019复合增长率(CAGR)为-1%。2020年1-9月，乙肝免疫球蛋白批签发总量为135万瓶，同比上升7%；2020年9月份，乙肝免疫球蛋白批签发量为36万瓶，同比增长257%；2020年三季度，乙肝免疫球蛋白批签发量为63万瓶，同比增长245%。2020年1-9月，共7家公司获批签发，分别为四川远大获批45万瓶(份额34%)，同比增长277%；华兰生物获批38万瓶(份额29%)，同比增长50%；天坛生物17万瓶(份额13%)，同比下降39%；泰邦生物获批8万瓶(份额7%)，同比下降7%；博雅生物获批7万瓶(份额6%)，去年同期无批签发。(规格换算/100IU)乙肝免疫球蛋白过去三年分季度批签发份额占比2008-2020M9乙肝免疫球蛋白批签发份额占比6.乙肝免疫球蛋白：同比增长7%，前两家份额超六成过去十年乙肝免疫球蛋白批签发量呈缓慢下降趋势。2008年以来，乙肝免疫球蛋白批签发份额波动较大，总体上批签发量较高的企业为华兰生物(占总量7%~29%)、天坛生物(占总量7%~46%)、四川远大(占总量9%~29%)。2020年9月份，乙肝免疫球蛋白获批36万瓶，同比增长257%，上海莱士获批15万瓶，同比增长1394%，华兰生物获批10万瓶，南岳生物获批4万瓶，四川远大获批7万瓶，同比增长268%。数据来源：药智网，中检院，西南证券整理266.乙肝免疫球蛋白：同比增长7%，前两家份额超六成2020M1-M9乙肝免疫球蛋白批签发数量及同比增速27血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长2019年1-9月2020年1-9月2019年9月2020年9月乙型肝炎免疫球蛋白（规格换算/100IU）博雅生物0.007.35/0.000.00/华兰生物25.5938.4550%0.009.78/南岳生物12.133.67-70%0.003.67/上海莱士39.8514.94-63%1.0014.941394%四川远大11.8744.71277%2.007.36268%泰邦生物9.128.49-7%3.000.00/天坛生物27.6816.93-39%4.000.00/合计126.25134.547%10.0035.75257%7.凝血酶原复合物：同比增长43%，泰邦生物约占六成市场份额2008-2020M9凝血酶原复合物批签发数量2020M1-M9凝血酶原复合物批签发占比数据来源：药智网，中检院，西南证券整理28凝血酶原复合物批签发2008-2019年CAGR为+28%。2008-2006年快速增长，2017年受两票制影响，行业整体处于去库存周期，批签发相对平稳。2020年1-9月批签发量有明显增长。2020年1-9月，凝血酶原复合物批签发总量为113万瓶，同比增长43%；2020年9月，凝血酶原复合物批签发量为16万瓶，同比上升112%；2020年三季度，凝血酶原复合物批签发量为33万瓶，同比下降20%。（规格换算/200IU）2020年1-9月,凝血酶原复合物批签发市场主要3家公司占据，分别为泰邦生物65万瓶(份额57%)和华兰生物45万瓶(份额39%)，南岳生物3万瓶(份额3%),泰邦生物的市场份额持续稳定。7.凝血酶原复合物：同比增长43%，泰邦生物约占六成市场份额2008-2020M9凝血酶原复合物批签发份额占比凝血酶原复合物过去三年分季度批签发份额占比数据来源：药智网，中检院，西南证券整理292008-2014年间，华兰生物的凝血酶原复合物批签发份额占70%以上。2015年以后，国内凝血酶原复合物批签发企业以泰邦生物与华兰生物为主。上海新兴事件过后，国内凝血酶原复合物生产企业只有泰邦生物与华兰生物两家。2015-2020年9月，华兰生物批签发份额为36%~75%，泰邦生物批签发份额为12%~64%。2020年9月，凝血酶原复合物批签发量为16万瓶，其中泰邦生物获批7万瓶(+99%)，华兰生物获批7万瓶(+75%)。7.凝血酶原复合物：同比增长43%，泰邦生物约占六成市场份额数据来源：药智网，中检院，西南证券整理302020M1-M9凝血酶原复合物批签发数量及同比增速血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长2019年1-9月2020年1-9月2019年9月2020年9月凝血酶原复合物（规格换算/200IU）华兰生物34.6545.3131%4.157.2775%南岳生物0.003.43/0.001.95/泰邦生物43.7664.7448%3.416.7899%中国新兴0.990.00/0.000.00/合计79.40113.4843%7.5616.00112%8.凝血因子Ⅷ：同比增长达27%，上海莱士、华兰生物份额达58%2008-2020M9凝血因子Ⅷ批签发数量凝血因子VIII行业2008-2019年CAGR为-2%，自2011年以来批签发量稳步增长。2020年1-9月，凝血因子Ⅷ批签发总量为166万瓶，同比增长27%；2020年9月，凝血因子Ⅷ批签发量为22万瓶，同比上升41%；2020年三季度，凝血因子Ⅷ批签发量为65万瓶，同比上升11%。（规格换算/200IU）2020年1-9月共有5家公司获批凝血因子Ⅷ，其中上海莱士获批53万瓶(份额32%)，同比增长244%；华兰生物获批43万瓶(份额26%)，同比下降12%；泰邦生物获批43万瓶(份额26%)，同比下降8%；绿十字获批26万瓶(份额16%)，同比增长39%。2020M1-M9凝血因子VIII批签发占比数据来源：药智网，中检院，西南证券整理318.凝血因子Ⅷ：同比增长达27%，上海莱士、华兰生物份额达58%2008-2020M9凝血因子Ⅷ批签发份额占比凝血因子Ⅷ过去三年分季度批签发份额占比2008-2020年9月，批签发量最高的企业分别是华兰生物(占总量24%~61%)、上海莱士(占总量9%~44%)、绿十字(占总量7%~46%)。2020年9月，凝血因子Ⅷ批签发量为22万瓶，同比上升41%。泰邦生物获批10万瓶(份额46%)，同比上升17%；上海莱士获批5万瓶(份额23%)，同比增长48%；华兰生物获批5万瓶(份额23%)，同比上升46%；绿十字获批2万瓶(份额7%)，去年同期无获批。数据来源：药智网，中检院，西南证券整理328.凝血因子Ⅷ：同比增长达27%，上海莱士、华兰生物份额达58%2020M1-M9凝血因子VIII批签发数量及同比增速数据来源：药智网，中检院，西南证券整理33血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长2019年1-9月2020年1-9月2019年9月2020年9月凝血因子VIII（规格换算/200IU）华兰生物48.9442.96-12%3.535.1546%绿十字19.0426.4839%0.001.65/上海莱士15.3752.92244%3.495.1548%泰邦生物46.8142.86-8%8.5610.0117%天坛生物0.000.37/0.000.00/总计130.16165.5927%15.5721.9641%9.纤维蛋白原：同比增长达17%，上海莱士、泰邦生物份额达73%2008-2020M9纤维蛋白原批签发数量纤维蛋白原2008-2019年CAGR为+49%，自2016年以来批签发量略有下滑。2020年1-9月，纤维蛋白原批签发总量为82万瓶，同比增长17%；2020年9月，纤维蛋白原批签发量为6万瓶，同比增长20%；2020年三季度，纤维蛋白原批签发量为19万瓶，同比下降22%。（规格换算/0.5g）2020年1-9月，纤维蛋白原共有6家公司获批签发，上海莱士获批39万瓶(份额47%)，同比增长1611%；泰邦生物获批21万瓶(份额26%)，同比下降26%；博雅生物获批13万瓶(份额16%)，同比下降53%；派斯菲科获批5万瓶(份额6%)，同比增长56%；绿十字获批3万瓶(份额4%)，同比下降41%。2020M1-M9纤维蛋白原批签发情况占比数据来源：药智网，中检院，西南证券整理349.纤维蛋白原：同比增长达17%，上海莱士、泰邦生物份额达73%纤维蛋白原过去三年分季度批签发份额占比2008-2020M9纤维蛋白原批签发份额占比过去十年，纤维蛋白原批签发量最高的是上海莱士，博雅生物。近几年泰邦生物、华兰生物等公司进入纤维蛋白原市场，市场占比逐渐分散。2010-2020年9月，批签发量较高的企业分别为博雅生物(占总量8%~57%)、上海莱士(占总量13%~55%)。2020年9月批签发量较低，仅有上海莱士获批6万瓶，去年同期无获批。数据来源：药智网，中检院，西南证券整理359.纤维蛋白原：同比增长达17%，上海莱士、泰邦生物份额达73%2020M1-M9纤维蛋白原批签发数量及同比增速数据来源：药智网，中检院，西南证券整理36血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长2019年1-9月2020年1-9月2019年9月2020年9月纤维蛋白原（规格换算/0.5g）博雅生物27.3312.92-53%0.000.00/华兰生物0.240.00/0.000.00/派斯菲科3.094.8256%0.000.00/上海莱士2.2538.501611%0.005.52/泰邦生物28.5221.05-26%3.150.00/卫光生物0.001.07/0.000.00/中国新兴2.840.00/0.000.00/绿十字(中国）5.703.37-41%1.460.00/总计69.9781.7217%4.625.5220%分公司来看：华兰生物:1-9月共8个品种获批。PCC获批45万瓶(+31%)，破免获批99万瓶(+24%)同比快速增长；人白获批203万瓶(+8%)，同比增速稳定；凝血因子VIII获批43万瓶(-12%)，同比小幅下降。双林生物:1-9月共4个品种获批。静丙获批47万瓶(+22%)，狂免获批90万瓶(-19%)，人白获批64万瓶(-12%)。卫光生物:1-9月共6个品种获批。狂免获批136万瓶(+43%)，同比快速增长；人白获批82万瓶（+25%），免疫球蛋白获批27万瓶(+4%)，同比稳定增长；破免获批5万瓶(-78%)，同比大幅下降。天坛生物:1-9月共7个品种获批。静丙获批257万瓶(+9%)，人白获批370万瓶(+7%)，同比稳定增长；破免获批51万瓶(-52%)，乙免获批17万瓶(-39%)，狂免获批67万瓶(-15%)，同比下降明显。上海莱士:1-9月共9个品种获批，多数品种批签发量同比快速增长。纤原获批39万瓶(+1611%)，凝血因子VIII获批53万瓶(+244%)，冻干静丙获批39万瓶(+81%)，静丙获批159万瓶(+67%)，人白获批227万瓶(+15%)。博雅生物:1-9月共5个品种获批，人白获批112万瓶(+81%)，同比大幅增长；狂免获批70万瓶(+34%)，静丙获批53万瓶(+28%)，同比增幅明显；纤原获批13万瓶(-53%)，同比明显下降。博晖创新:1-9月共5个品种获批。整体批签发量快速增长。免疫球蛋白批签发量为70万瓶(+254%)，冻干静丙获批44万瓶(+151%)，人白获批41万瓶（+25%），狂免获批16万瓶(+17%)，同比大幅增长。泰邦生物:1-9月共9个品种获批。PCC获批65万瓶(+48%)，同比快速增长；人白获批283万瓶(-9%)，同比下降。2020年1-9月血制品公司批签发情况37共8个品种获批。PCC获批45万瓶(+29%)，破免获批99万瓶(+24%)，同比快速增长；人白获批203万瓶(+8%)，同比增速稳定；凝血因子VIII获批43万瓶(-12%)，同比小幅下降。2020年9月共8种血制品获批，其中PCC获批7万瓶(+57%)，凝血因子Ⅷ获批5万瓶(+46%)，乙免获批10万瓶，去年同期无批签发，破免获批5万瓶(-82%)，狂免获批10万瓶(-72%)，静丙获批14万瓶(-22%)，人白获批26万瓶(-11%)，乙免获批10万瓶，去年同期无批签发。华兰生物(002007)：破免同比增长24%数据来源：药智网，中检院，西南证券整理2020M1-M9华兰生物批签发数量及同比增长38血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-9月2020年1-9月2019年9月2020年9月人血白蛋白（规格换算/10g）华兰生物188.39202.698%29.1526.00-11%静注人免疫球蛋白（规格换算/2.5g）102.9199.68-3%18.3814.32-22%狂犬病免疫球蛋白（规格换算/200IU）98.1064.41-34%34.349.78-72%破伤风免疫球蛋白（规格换算/250IU）79.9498.9524%30.245.48-82%免疫球蛋白（规格换算/150mg）21.0312.51-41%6.206.281%乙型肝炎免疫球蛋白（规格换算/100IU）25.5938.4550%0.009.78/凝血因子VIII（规格换算/200IU）48.9442.96-12%3.535.1546%凝血酶原复合物（规格换算/200IU）34.6545.3131%4.157.2775%华兰生物凝血酶原复合物批签发情况(万瓶换算200IU，按年份)华兰生物凝血因子VIII批签发情况(万瓶换算200IU，按年份)数据来源：药智网，中检院，西南证券整理华兰生物人血白蛋白批签发情况(万瓶换算10g，按年份)华兰生物静丙批签发情况(万瓶换算2.5g，按年份)39华兰生物(002007)：破免同比增长24%华兰生物破伤风免疫球蛋白批签发情况(万瓶换算250IU，按年份)华兰生物乙肝免疫球蛋白批签发情况(万瓶换算100IU，按年份)数据来源：药智网，中检院，西南证券整理华兰生物狂犬病免疫球蛋白批签发情况(万瓶换算200IU，按年份)华兰生物免疫球蛋白批签发情况(万瓶换算150mg，按年份)40华兰生物(002007)：破免同比增长24%双林生物：共4个品种获批。静丙获批47万瓶(+22%)，狂免获批90万瓶(-19%)，人白获批64万瓶（-12%）2020年9月共有1种血制品获批，静丙获批7万瓶(+33%)双林生物(000403)：静丙同比增长22%，人白下降明显数据来源：药智网，中检院，西南证券整理2020M1-M9双林生物批签发数量及同比增长41血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-9月2020年1-9月2019年9月2020年9月人血白蛋白（规格换算/10g）双林生物72.9464.39-12%7.640.00/静注人免疫球蛋白（规格换算/2.5g）38.8447.3422%5.537.3833%狂犬病免疫球蛋白（规格换算/200IU）111.1890.30-19%0.000.00/破伤风免疫球蛋白（规格换算/250IU）35.7035.790%0.000.00/双林生物人血白蛋白批签发情况(万瓶换算10g，按年份)双林生物静丙批签发情况(万瓶换算成2.5g，按年份)双林生物狂犬病免疫球蛋白批签发情况(万瓶换算200IU，按年份)双林生物破伤风免疫球蛋白批签发情况(万瓶换算250IU，按年份)数据来源：药智网，中检院，西南证券整理42双林生物(000403)：静丙同比增长22%，人白下降明显卫光生物：共6个品种获批。狂免获批136万瓶(+43%)，同比快速增长；人白获批82万瓶（+25%），免疫球蛋白获批27万瓶(+4%)，同比稳定增长；破免获批5万瓶(-78%)，同比大幅下降。2020年9月有4种血制品获批，免疫球蛋白获批19万瓶，同期无获批，人白获批8万瓶，同期无获批，静丙获批2万瓶(-67%)，狂免获批10万瓶(-66%)。卫光生物(002880)：狂免同比增长43%，破免同比下降78%数据来源：药智网，中检院，西南证券整理2020M1-M9卫光生物批签发数量及同比增长43血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-9月2020年1-9月2019年9月2020年9月人血白蛋白（规格换算/10g）卫光生物65.5881.9224.92%0.008.05/静注人免疫球蛋白（规格换算/2.5g）42.2248.4814.82%5.511.80-67.27%狂犬病免疫球蛋白（规格换算/200IU）94.94136.1243.37%29.2610.05-65.64%破伤风免疫球蛋白（规格换算/250IU）21.134.62-78.12%0.000.00/免疫球蛋白（规格换算/150mg）26.0227.064.02%0.0019.27/纤维蛋白原（规格换算/0.5g）0.001.07/0.000.00/卫光生物人血白蛋白批签发情况(万瓶换算成10g，按年份)卫光生物狂犬病免疫球蛋白批签发情况(万瓶换算成200IU，按年份)卫光生物静丙批签发情况(万瓶换算成2.5g，按年份)卫光生物破伤风免疫球蛋白批签发情况(万瓶换算250IU，按年份)数据来源：药智网，中检院，西南证券整理卫光生物(002880)：狂免同比增长43%，破免同比下降78%44天坛生物：共7个品种获批。静丙获批257万瓶(+9%)，人白获批370万瓶(+7%)，同比稳定增长；破免获批51万瓶(-52%)，乙免获批17万瓶(-39%)，狂免获批67万瓶(-15%)，同比下降明显。2020年9月共2种血制品获批，人白获批31万瓶(-33%)，静丙获批34万瓶(-14%)，。天坛生物(600161)：狂免同比下降-15%，破免同比下降52%数据来源：药智网，中检院，西南证券整理2020M1-M9天坛生物批签发数量及同比增长45血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-9月2020年1-9月2019年9月2020年9月人血白蛋白（规格换算/10g）天坛生物346.96370.247%45.9531.01-33%静注人免疫球蛋白（规格换算/2.5g）236.65257.049%39.0133.60-14%狂犬病免疫球蛋白（规格换算/200IU）78.4766.74-15%25.640.00/破伤风免疫球蛋白（规格换算/250IU）107.2950.97-52%0.000.00/免疫球蛋白（规格换算/150mg）0.004.49/0.000.00/乙型肝炎免疫球蛋白（规格换算/100IU）27.6816.93-39%4.000.00/冻干静注人免疫球蛋白（规格换算/1.0g）0.004.83/0.000.00/天坛生物人血白蛋白批签发情况(万瓶换算成10g，按年份)天坛生物静丙批签发情况(万瓶换算成2.5g，按年份)数据来源：药智网，中检院，西南证券整理46天坛生物(600161)：狂免同比下降-15%，破免同比下降52%天坛生物狂犬病免疫球蛋白批签发情况(万瓶换算200IU，按年份)天坛生物破伤风免疫球蛋白批签发情况(万瓶换算250IU，按年份)天坛生物乙肝免疫球蛋白批签发情况(万瓶换算100IU，按年份)数据来源：药智网，中检院，西南证券整理天坛生物免疫球蛋白批签发情况(万瓶换算150mg，按年份)47天坛生物(600161)：狂免同比下降-15%，破免同比下降52%•上海莱士：共9个品种获批，多数品种批签发量较去年同期快速增长。纤原获批39万瓶(+1611%)，凝血因子VIII获批53万瓶(+244%)，冻干静丙获批39万瓶(+81%)，静丙获批159万瓶(+67%)，人白获批227万瓶(+15%)。•2020年9月共5种血制品获批，其中凝血因子Ⅷ获批5万瓶(+48%)上海莱士(002252)：纤原同比增长高达1611%数据来源：药智网，中检院，西南证券整理2020M1-M9上海莱士批签发数量及同比增长48血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-9月2020年1-9月2019年9月2020年9月人血白蛋白（规格换算/10g）上海莱士197.37226.9715%38.6321.94-43%静注人免疫球蛋白（规格换算/2.5g）95.07158.5567%40.868.41-79%狂犬病免疫球蛋白（规格换算/200IU）139.9873.76-47%38.990.00/破伤风免疫球蛋白（规格换算/250IU）39.6246.3917%11.080.00/免疫球蛋白（规格换算/150mg）28.6627.04-6%0.000.00/乙型肝炎免疫球蛋白（规格换算/100IU）39.8514.94-63%1.0014.941394%冻干静注人免疫球蛋白（规格换算/1.0g）21.6139.1081%0.000.00/凝血因子VIII（规格换算/200IU）15.3752.92244%3.495.1548%纤维蛋白原（规格换算/0.5g）2.2538.501611%0.005.52/上海莱士纤维蛋白原批签发情况(万瓶换算成0.5g，按年份)上海莱士凝血因子VIII批签发情况(万瓶换算200IU，按年份)上海莱士人血白蛋白批签发情况(万瓶换算成10g，按年份)上海莱士静丙批签发情况(万瓶换算成2.5g，按年份)数据来源：药智网，中检院，西南证券整理49上海莱士(002252)：纤原同比增长高达1611%上海莱士破伤风免疫球蛋白批签发情况(万瓶换算250IU，按年份)上海莱士乙肝免疫球蛋白批签发情况(万瓶换算100IU，按年份)上海莱士狂犬病免疫球蛋白批签发情况(万瓶换算200IU，按年份)上海莱士免疫球蛋白批签发情况(万瓶换算150mg，按年份)数据来源：药智网，中检院，西南证券整理50上海莱士(002252)：纤原同比增长高达1611%•博雅生物：1-9月共5个品种获批，人白获批112万瓶(+81%)，同比大幅增长；狂免获批70万瓶(+34%)，静丙获批53万瓶(+28%)，同比增幅明显；纤原获批13万瓶(-53%)，同比明显下降。•2020年9月共3种血制品获批，人白获批16万瓶(62%)、静丙获批5万瓶(+100%)。博雅生物(300294)：人白、狂免同比增长超34%数据来源：药智网，中检院，西南证券整理2020M1-M9博雅生物批签发数量及同比增长51血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-9月2020年1-9月2019年9月2020年9月人血白蛋白（规格换算/10g）博雅生物61.75112.0181%9.6915.7462%静注人免疫球蛋白（规格换算/2.5g）41.5753.0128%2.575.15100%狂犬病免疫球蛋白（规格换算/200IU）52.3270.1434%13.519.43-30%免疫球蛋白（规格换算/150mg）0.0021.40/0.000.00/乙型肝炎免疫球蛋白（规格换算/100IU）2.650.00/0.000.00/纤维蛋白原（规格换算/0.5g）27.3312.92-52.73%0.000.00/博雅生物纤维蛋白原批签发情况(万瓶换算成0.5g，按年份)博雅生物乙型肝炎免疫蛋白批签发情况(万瓶换算100IU，按年份)数据来源：药智网，中检院，西南证券整理博雅生物人血白蛋白批签发情况(万瓶，换算成10g，按年份)博雅生物静丙批签发情况(万瓶换算成2.5g，按年份)52博雅生物(300294)：人白、狂免同比增长超34%博雅生物狂犬病免疫球蛋白批签发情况(万瓶，换算成200IU，按年份)数据来源：药智网，中检院，西南证券整理博雅生物免疫球蛋白批签发情况(万瓶换算150mg，按年份)53博雅生物(300294)：人白、狂免同比增长超34%•博晖创新：共5个品种获批。整体批签发量快速增长。免疫球蛋白批签发量为70万瓶(+254%)，冻干静丙获批44万瓶(+151%)，人白获批41万瓶（+25%），狂免获批16万瓶(+17%)，同比快速增长。•2020年9月，共1种血制品获批,人白获批3万瓶(-30%)博晖创新(300318)：冻干静丙、免疫球蛋白同比增长超100%数据来源：药智网，中检院，西南证券整理2020M1-M9博晖创新批签发数量及同比增长54血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-9月2020年1-9月2019年9月2020年9月人血白蛋白（规格换算/10g）博晖创新33.0241.2024.75%3.792.64-30.30%狂犬病免疫球蛋白（规格换算/200IU）13.4615.7617.08%6.170.00/破伤风免疫球蛋白（规格换算/250IU）5.251.98-62.33%0.000.00/免疫球蛋白（规格换算/150mg）19.8970.49254.46%0.000.00/冻干静注人免疫球蛋白（规格换算/1.0g）17.4643.74150.60%6.240.00/数据来源：药智网，中检院，西南证券整理55博晖创新(300318)：冻干静丙、免疫球蛋白同比增长超100%博晖创新人血白蛋白批签发情况(万瓶换算成10g，按年份)博晖创新冻干静丙批签发情况(万瓶换算成2.5g，按年份)博晖创新狂犬病免疫球蛋白批签发情况(万瓶换算200IU，按年份)博晖创新破伤风免疫球蛋白批签发情况(万瓶换算150mg，按年份)博晖创新免疫球蛋白批签发情况(万瓶换算成150mg，按年份)数据来源：药智网，中检院，西南证券整理56博晖创新(300318)：冻干静丙、免疫球蛋白同比增长超100%•泰邦生物：共9个品种获批。PCC获批65万瓶(+48%)，同比快速增长；人白获批283万瓶(-9%)，同比快速下降。•2020年9月共6种血制品获批，PCC获批7万瓶(+99%)，人白获批35万瓶(+18%)，凝血因子Ⅷ获批10万瓶(+17%)，同比快速增长；狂免获批14万瓶(-55%)，静丙获批11万瓶(-47%)，破免获批9万瓶(-30%)，同比下降明显。泰邦生物(CBPO.O)：PCC同比增长超30%数据来源：药智网，中检院，西南证券整理2020M1-M9泰邦生物批签发数量及同比增长57血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-9月2020年1-9月2019年9月2020年9月人血白蛋白（规格换算/10g）泰邦生物310.24283.17-9%29.5334.9718%静注人免疫球蛋白（规格换算/2.5g）169.28144.10-15%21.5811.48-47%狂犬病免疫球蛋白（规格换算/200IU）128.79147.8415%29.9813.56-55%破伤风免疫球蛋白（规格换算/250IU）134.08104.93-22%24.548.59-65%免疫球蛋白批签发量（万瓶）8.609.287.90%0.000.00/乙型肝炎免疫球蛋白（规格换算/100IU）9.128.49-6.92%3.000.00/凝血因子VIII（规格换算/200IU）46.8142.86-8.43%8.5610.0117.04%凝血酶原复合物（规格换算/200IU）43.7664.7447.97%3.416.7899.00%纤维蛋白原（规格换算/0.5g）28.5221.05-26.21%3.150.00/泰邦生物凝血因子VIII批签发情况(万瓶换算200IU，按年份)泰邦生物狂犬病免疫球蛋白批签发情况(万瓶换算200IU，按年份)泰邦生物静丙批签发情况(万瓶换算成2.5g，按年份)泰邦生物人血白蛋白批签发情况(万瓶换算成10g，按年份)数据来源：药智网，中检院，西南证券整理58泰邦生物(CBPO.O)：PCC同比增长超30%泰邦生物破伤风免疫球蛋白批签发情况(万瓶换算150mg，按年份)泰邦生物乙肝免疫球蛋白批签发情况(万瓶换算100IU，按年份)泰邦生物纤维蛋白原批签发情况(万瓶换算成0.5g，按年份)泰邦生物凝血酶原复合物批签发情况(万瓶换算200IU，按年份)数据来源：药智网，中检院，西南证券整理59泰邦生物(CBPO.O)：PCC同比增长超30%泰邦生物免疫球蛋白批签发情况(万瓶换算150mg，按年份)数据来源：药智网，中检院，西南证券整理60泰邦生物(CBPO.O)：PCC同比增长超30%西南证券研究发展中心西南证券投资评级说明公司评级买入：未来6个月内，个股相对沪深300指数涨幅在20%以上持有：未来6个月内，个股相对沪深300指数涨幅介于10%与20%之间中性：未来6个月内，个股相对沪深300指数涨幅介于-10%与10%之间回避：未来6个月内，个股相对沪深300指数涨幅介于-20%与-10%之间卖出：未来6个月内，个股相对沪深300指数涨幅在-20%以下行业评级强于大市：未来6个月内，行业整体回报高于沪深300指数5%以上跟随大市：未来6个月内，行业整体回报介于沪深300指数-5%与5%之间弱于大市：未来6个月内，行业整体回报低于沪深300指数-5%以下分析师承诺报告署名分析师具有中国证券业协会授予的证券投资咨询执业资格并注册为证券分析师，报告所采用的数据均来自合法合规渠道，分析逻辑基于分析师的职业理解，通过合理判断得出结论，独立、客观地出具本报告。分析师承诺不曾因，不因，也将不会因本报告中的具体推荐意见或观点而直接或间接获取任何形式的补偿。重要声明西南证券股份有限公司（以下简称“本公司”）具有中国证券监督管理委员会核准的证券投资咨询业务资格。本公司与作者在自身所知情范围内，与本报告中所评价或推荐的证券不存在法律法规要求披露或采取限制、静默措施的利益冲突。《证券期货投资者适当性管理办法》于2017年7月1日起正式实施，本报告仅供本公司客户中的专业投资者使用，若您并非本公司客户中的专业投资者，为控制投资风险，请取消接收、订阅或使用本报告中的任何信息。本公司也不会因接收人收到、阅读或关注自媒体推送本报告中的内容而视其为客户。本公司或关联机构可能会持有报告中提到的公司所发行的证券并进行交易，还可能为这些公司提供或争取提供投资银行或财务顾问服务。本报告中的信息均来源于公开资料，本公司对这些信息的准确性、完整性或可靠性不作任何保证。本报告所载的资料、意见及推测仅反映本公司于发布本报告当日的判断，本报告所指的证券或投资标的的价格、价值及投资收入可升可跌，过往表现不应作为日后的表现依据。在不同时期，本公司可发出与本报告所载资料、意见及推测不一致的报告，本公司不保证本报告所含信息保持在最新状态。同时，本公司对本报告所含信息可在不发出通知的情形下做出修改，投资者应当自行关注相应的更新或修改。本报告仅供参考之用，不构成出售或购买证券或其他投资标的要约或邀请。在任何情况下，本报告中的信息和意见均不构成对任何个人的投资建议。投资者应结合自己的投资目标和财务状况自行判断是否采用本报告所载内容和信息并自行承担风险，本公司及雇员对投资者使用本报告及其内容而造成的一切后果不承担任何法律责任。本报告及附录版权为西南证券所有，未经书面许可，任何机构和个人不得以任何形式翻版、复制和发布。如引用须注明出处为“西南证券”，且不得对本报告及附录进行有悖原意的引用、删节和修改。未经授权刊载或者转发本报告及附录的，本公司将保留向其追究法律责任的权利。西南证券研究发展中心上海重庆地址：上海市浦东新区陆家嘴东路166号中国保险大厦20楼地址：重庆市江北区桥北苑8号西南证券大厦3楼邮编：200120邮编：400023北京深圳地址：北京市西城区南礼士路66号建威大厦1501-1502地址：深圳市福田区深南大道6023号创建大厦4楼邮编：100045邮编：518040西南证券机构销售团队区域姓名职务座机手机邮箱上海蒋诗烽地区销售总监021-6841530918621310081jsf@swsc.com.cn张方毅高级销售经理021-6841395915821376156zfyi@swsc.com.cn杨博睿销售经理021-6841586113166156063ybz@swsc.com.cn吴菲阳销售经理021-6841502016621045018wfy@swsc.com.cn付禹销售经理021-6841552313761585788fuyu@swsc.com.cn黄滢销售经理1881821559318818215593hying@swsc.com.cn蒋俊洲销售经理1851651610518516516105jiangjz@swsc.com.cn刘琦销售经理1861275119218612751192liuqi@swsc.com.cn崔露文销售经理1564296031515642960315clw@swsc.com.cn陈慧琳销售经理1852348777518523487775chhl@swsc.com.cn北京张岚高级销售经理1860124180318601241803zhanglan@swsc.com.cn彭博销售经理1339169933913391699339pbyf@swsc.com.cn高妍琳销售经理1581080951115810809511gyl@swsc.com.cn广深王湘杰地区销售副总监0755-2667151713480920685wxj@swsc.com.cn林芷豌高级销售经理1501258512215012585122linzw@swsc.com.cn陈慧玲高级销售经理1850070933018500709330chl@swsc.com.cn谭凌岚销售经理1364236260113642362601tll@swsc.com.cn郑龑销售经理1882518974418825189744zhengyan@swsc.com.cn西南证券研究发展中心","data":[{"id":"1","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年1-9月，人血白蛋白批签发总量为4554万瓶(+18%)","content_offset":["146","179"],"indicators":[{"indicator_name":"批签发量","indicator_value":["4554万瓶","167","173"],"indicator_element":{"时间":["2020年1-9月","146","155"],"产品":["人血白蛋白","156","161"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年1-9月，人血白蛋白批签发总量为4554万瓶(+18%)","content_offset":["146","179"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["18%","175","178"],"indicator_element":{"时间":["2020年1-9月","146","155"],"产品":["人血白蛋白","156","161"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"其中国产人血白蛋白批签发总量为1668万瓶(+3%)","content_offset":["180","206"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1668万瓶","195","201"],"indicator_element":{"时间":["2020年1-9月","146","155"],"产品":["人血白蛋白","184","189"],"渠道":["国产","182","184"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"其中国产人血白蛋白批签发总量为1668万瓶(+3%)","content_offset":["180","206"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["3%","203","205"],"indicator_element":{"时间":["2020年1-9月","146","155"],"产品":["人血白蛋白","184","189"],"渠道":["国产","182","184"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"占比为37%","content_offset":["207","213"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["37%","210","213"],"indicator_element":{"时间":["2020年1-9月","146","155"],"产品":["人血白蛋白","130","135"],"渠道":["国产","182","184"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"进口人血白蛋白批签发总量为2878万瓶(+29%)","content_offset":["214","239"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2878万瓶","227","233"],"indicator_element":{"时间":["2020年1-9月","146","155"],"产品":["人血白蛋白","216","221"],"渠道":["进口","214","216"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"进口人血白蛋白批签发总量为2878万瓶(+30%)","content_offset":["-1","-1"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["30%","20","23"],"indicator_element":{"时间":["2020年1-9月","15","24"],"产品":["人血白蛋白","1","6"],"渠道":["进口","-1","1"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"占比为63%","content_offset":["240","246"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["63%","243","246"],"indicator_element":{"时间":["2020年1-9月","146","155"],"产品":["人血白蛋白","156","161"],"渠道":["进口","214","216"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年1-9月，静丙（规格换算/2.5g）批签发总量为1003万瓶","content_offset":["253","288"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1003万瓶","282","288"],"indicator_element":{"时间":["2020年1-9月","253","262"],"产品":["静丙","263","265"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比增长11%","content_offset":["289","296"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["11%","293","296"],"indicator_element":{"时间":["2020年1-9月","253","262"],"产品":["静丙","263","265"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年9月静丙批签发量为89万瓶","content_offset":["300","318"],"indicators":[{"indicator_name":"批签发量","indicator_value":["89万瓶","314","318"],"indicator_element":{"时间":["2020年9月","300","307"],"产品":["静丙","307","309"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比下降45%","content_offset":["319","326"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降45%","321","326"],"indicator_element":{"时间":["2020年9月","300","307"],"产品":["静丙","263","265"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"其他品种如狂免（规格换算/200IU）855万瓶(-6%)、破免（规格换算/250IU）411万瓶(-17%)","content_offset":["327","382"],"indicators":[{"indicator_name":"批签发量","indicator_value":["855万瓶","346","351"],"indicator_element":{"产品":["狂免","332","334"],"时间":["2020年1-9月","253","262"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["411万瓶","371","376"],"indicator_element":{"产品":["破免","357","359"],"时间":["2020年1-9月","253","262"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"其他品种如狂免（规格换算/200IU）855万瓶(-6%)、破免（规格换算/250IU）411万瓶(-17%)","content_offset":["327","382"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-6%","352","355"],"indicator_element":{"产品":["狂免","332","334"],"时间":["2020年1-9月","253","262"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-17%","377","381"],"indicator_element":{"产品":["破免","357","359"],"时间":["2020年1-9月","253","262"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"免疫球蛋白（规格换算/150mg）240万瓶(+110%)","content_offset":["383","412"],"indicators":[{"indicator_name":"批签发量","indicator_value":["240万瓶","400","405"],"indicator_element":{"时间":["2020年1-9月","850","859"],"产品":["免疫球蛋白","383","388"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"免疫球蛋白（规格换算/150mg）240万瓶(+110%)","content_offset":["383","412"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+110%","406","411"],"indicator_element":{"时间":["2020年1-9月","850","859"],"产品":["免疫球蛋白","383","388"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"PCC（规格换算/200IU）113万瓶(+43%)、凝血因子VIII（规格换算/200IU）165万瓶(+27%)、纤原（规格换算/0.5g）81万瓶(+17%)","content_offset":["419","501"],"indicators":[{"indicator_name":"批签发量","indicator_value":["113万瓶","434","439"],"indicator_element":{"产品":["PCC","419","422"],"时间":["2020年1-9月","850","859"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["165万瓶","466","471"],"indicator_element":{"产品":["凝血因子VIII","446","454"],"时间":["2020年1-9月","850","859"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["81万瓶","491","495"],"indicator_element":{"产品":["纤原","478","480"],"时间":["2020年1-9月","850","859"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"PCC（规格换算/200IU）113万瓶(+43%)、凝血因子VIII（规格换算/200IU）165万瓶(+27%)、纤原（规格换算/0.5g）81万瓶(+17%)","content_offset":["419","501"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+43%","440","444"],"indicator_element":{"产品":["PCC","419","422"],"时间":["2020年1-9月","850","859"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+27%","472","476"],"indicator_element":{"产品":["凝血因子VIII","446","454"],"时间":["2020年1-9月","850","859"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+17%","496","500"],"indicator_element":{"产品":["纤原","478","480"],"时间":["2020年1-9月","850","859"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"人血白蛋白：1-9月同比增长18%","content_offset":["2163","2180"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["18%","2177","2180"],"indicator_element":{"时间":["1-9月","2169","2173"],"产品":["人血白蛋白","2163","2168"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"Q3同比-11%","content_offset":["2190","2198"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-11%","2194","2198"],"indicator_element":{"时间":["Q3","2190","2192"],"产品":["人血白蛋白","2163","2168"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"静丙：1-9月同比增长11%","content_offset":["2201","2215"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["11%","2212","2215"],"indicator_element":{"时间":["1-9月","2204","2208"],"产品":["静丙","2201","2203"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"Q3同比-34%","content_offset":["2230","2238"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-34%","2234","2238"],"indicator_element":{"时间":["Q3","2230","2232"],"产品":["静丙","2201","2203"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"免疫球蛋白：1-9月同比增长110%","content_offset":["2241","2259"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["110%","2255","2259"],"indicator_element":{"时间":["1-9月","2247","2251"],"产品":["免疫球蛋白","2241","2246"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"Q3同比-16%","content_offset":["2275","2283"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-16%","2279","2283"],"indicator_element":{"时间":["Q3","2275","2277"],"产品":["静丙","2201","2203"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"破伤风免疫球蛋白：1-9月同比下降17%","content_offset":["2329","2349"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降17%","2344","2349"],"indicator_element":{"时间":["1-9月","2338","2342"],"产品":["破伤风免疫球蛋白","2329","2337"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"Q3同比-41%","content_offset":["2318","2326"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-41%","2322","2326"],"indicator_element":{"时间":["Q3","2318","2320"],"产品":["破伤风免疫球蛋白","2329","2337"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"狂犬病免疫球蛋白：1-9月同比下降6%","content_offset":["2286","2305"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-6%","8253","8256"],"indicator_element":{"时间":["1-9月","2295","2299"],"产品":["狂犬病免疫球蛋白","2286","2294"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"Q3同比-41%","content_offset":["2318","2326"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-41%","2322","2326"],"indicator_element":{"时间":["Q3","2318","2320"],"产品":["狂犬病免疫球蛋白","2286","2294"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"乙肝免疫球蛋白：1-9月同比增长7%","content_offset":["2373","2391"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["7%","2389","2391"],"indicator_element":{"时间":["1-9月","2381","2385"],"产品":["乙肝免疫球蛋白","2373","2380"]},"indicator_supplement":{"属性":""}}]},{"id":"33","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"Q3同比+245%","content_offset":["2401","2410"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+245%","2405","2410"],"indicator_element":{"时间":["Q3","2401","2403"],"产品":["乙肝免疫球蛋白","2373","2380"]},"indicator_supplement":{"属性":""}}]},{"id":"34","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"凝血酶原复合物：1-9月同比增长43%","content_offset":["2413","2432"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["43%","2429","2432"],"indicator_element":{"时间":["1-9月","2421","2425"],"产品":["凝血酶原复合物","2413","2420"]},"indicator_supplement":{"属性":""}}]},{"id":"35","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"Q3同比-20%","content_offset":["2445","2453"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["","2445","2445"],"indicator_element":{"时间":["Q3","2445","2447"],"产品":["凝血酶原复合物","2413","2420"]},"indicator_supplement":{"属性":""}}]},{"id":"36","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"凝血因子Ⅷ：1-9月同比增长达27%","content_offset":["2456","2474"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["27%","2471","2474"],"indicator_element":{"时间":["1-9月","2462","2466"],"产品":["凝血因子Ⅷ","2456","2461"]},"indicator_supplement":{"属性":""}}]},{"id":"37","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"Q3同比+11%","content_offset":["2496","2504"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+11%","2500","2504"],"indicator_element":{"时间":["Q3","2496","2498"],"产品":["凝血因子Ⅷ","2456","2461"]},"indicator_supplement":{"属性":""}}]},{"id":"38","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"纤维蛋白原：1-9月同比增长达17%","content_offset":["2507","2525"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["17%","2522","2525"],"indicator_element":{"时间":["1-9月","2513","2517"],"产品":["纤维蛋白原","2507","2512"]},"indicator_supplement":{"属性":""}}]},{"id":"39","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"Q3同比-22%","content_offset":["2542","2550"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["","2542","2542"],"indicator_element":{"时间":["Q3","2542","2544"],"产品":["纤维蛋白原","2507","2512"]},"indicator_supplement":{"属性":""}}]},{"id":"40","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2007-2019年人血白蛋白批签发复合年均增长率(CAGR)为+22%","content_offset":["3431","3467"],"indicators":[{"indicator_name":"批签发量环比年复合增长率","indicator_value":["22%","3464","3467"],"indicator_element":{"时间":["2007-2019年","3431","3441"],"产品":["人血白蛋白","3441","3446"]},"indicator_supplement":{"属性":""}}]},{"id":"41","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2019年，国内人血白蛋白批签发量为5285万瓶(+11%)","content_offset":["3468","3498"],"indicators":[{"indicator_name":"批签发量","indicator_value":["5285万瓶","3486","3492"],"indicator_element":{"时间":["2019年","3468","3473"],"产品":["人血白蛋白","3476","3481"],"区域":["国内","3474","3476"]},"indicator_supplement":{"属性":""}}]},{"id":"42","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2019年，国内人血白蛋白批签发量为5285万瓶(+11%)","content_offset":["3468","3498"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["11%","3494","3497"],"indicator_element":{"时间":["2019年","3468","3473"],"产品":["人血白蛋白","3476","3481"],"区域":["国内","3474","3476"]},"indicator_supplement":{"属性":""}}]},{"id":"43","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"其中国产批签发为2120万瓶(+13%)","content_offset":["3499","3519"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2120万瓶","3507","3513"],"indicator_element":{"时间":["2019年","3436","3441"],"区域":["国内","3474","3476"],"产品":["人血白蛋白","3441","3446"],"渠道":["国产","3501","3503"]},"indicator_supplement":{"属性":""}}]},{"id":"44","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"其中国产批签发为2120万瓶(+13%)","content_offset":["3499","3519"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["14%","5297","5300"],"indicator_element":{"时间":["2019年","3436","3441"],"产品":["人血白蛋白","3441","3446"],"区域":["国内","3474","3476"],"渠道":["国产","3501","3503"]},"indicator_supplement":{"属性":""}}]},{"id":"45","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"占比40%","content_offset":["3520","3525"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["40%","3522","3525"],"indicator_element":{"时间":["2019年","3436","3441"],"区域":["国内","3474","3476"],"产品":["人血白蛋白","3441","3446"],"渠道":["国产","3501","3503"]},"indicator_supplement":{"属性":""}}]},{"id":"46","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"进口批签发为3165万瓶(+11%)","content_offset":["3526","3544"],"indicators":[{"indicator_name":"批签发量","indicator_value":["3165万瓶","3532","3538"],"indicator_element":{"时间":["2020年","3562","3567"],"产品":["人血白蛋白","3441","3446"],"渠道":["进口","3526","3528"]},"indicator_supplement":{"属性":""}}]},{"id":"47","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"进口批签发为3165万瓶(+11%)","content_offset":["3526","3544"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["11%","3540","3543"],"indicator_element":{"时间":["2021年","-1","-1"],"产品":["人血白蛋白","3441","3446"],"渠道":["进口","3526","3528"]},"indicator_supplement":{"属性":""}}]},{"id":"48","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"占比60%","content_offset":["3545","3550"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["60%","3547","3550"],"indicator_element":{"时间":["2022年","-1","-1"],"产品":["人血白蛋白","3476","3481"],"渠道":["进口","3526","3528"]},"indicator_supplement":{"属性":""}}]},{"id":"49","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"进口人血白蛋白批签发总量为2879万瓶(+29%)","content_offset":["3630","3655"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2879万瓶","3643","3649"],"indicator_element":{"时间":["2020年1-9月","3562","3571"],"产品":["人血白蛋白","3632","3637"],"渠道":["进口","3630","3632"]},"indicator_supplement":{"属性":""}}]},{"id":"50","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"进口人血白蛋白批签发总量为2879万瓶(+29%)","content_offset":["3630","3655"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["30%","5704","5707"],"indicator_element":{"时间":["2020年1-9月","3562","3571"],"产品":["人血白蛋白","3632","3637"],"渠道":["进口","3630","3632"]},"indicator_supplement":{"属性":""}}]},{"id":"51","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"占比为63%","content_offset":["240","246"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["","240","240"],"indicator_element":{"时间":["2020年1-9月","146","155"],"产品":["人血白蛋白","156","161"],"渠道":["进口","214","216"]},"indicator_supplement":{"属性":""}}]},{"id":"52","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年9月人血白蛋白批签发总量为510万瓶(-22%)","content_offset":["3663","3692"],"indicators":[{"indicator_name":"批签发量","indicator_value":["510万瓶","3681","3686"],"indicator_element":{"时间":["2020年9月","3663","3670"],"产品":["人血白蛋白","3670","3675"]},"indicator_supplement":{"属性":""}}]},{"id":"53","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年9月人血白蛋白批签发总量为510万瓶(-22%)","content_offset":["3663","3692"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-22%","3687","3691"],"indicator_element":{"时间":["2020年9月","3663","3670"],"产品":["人血白蛋白","3670","3675"]},"indicator_supplement":{"属性":""}}]},{"id":"54","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"其中国产人血白蛋白批签发量为164万瓶(-19%)","content_offset":["3693","3718"],"indicators":[{"indicator_name":"批签发量","indicator_value":["164万瓶","3707","3712"],"indicator_element":{"时间":["2020年9月","3663","3670"],"产品":["人血白蛋白","3697","3702"],"渠道":["国产","3695","3697"]},"indicator_supplement":{"属性":""}}]},{"id":"55","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"其中国产人血白蛋白批签发量为164万瓶(-19%)","content_offset":["3693","3718"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-19%","3713","3717"],"indicator_element":{"时间":["2020年9月","3663","3670"],"产品":["人血白蛋白","3697","3702"],"渠道":["国产","3695","3697"]},"indicator_supplement":{"属性":""}}]},{"id":"56","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"占比32%","content_offset":["3719","3724"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["32%","3721","3724"],"indicator_element":{"时间":["2020年9月","3663","3670"],"产品":["人血白蛋白","3632","3637"],"渠道":["国产","3695","3697"]},"indicator_supplement":{"属性":""}}]},{"id":"57","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"进口人血白蛋白批签发量为346万瓶(-23%)","content_offset":["3725","3748"],"indicators":[{"indicator_name":"批签发量","indicator_value":["346万瓶","3737","3742"],"indicator_element":{"时间":["2020年9月","3663","3670"],"产品":["人血白蛋白","3727","3732"],"渠道":["进口","3725","3727"]},"indicator_supplement":{"属性":""}}]},{"id":"58","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"进口人血白蛋白批签发量为346万瓶(-23%)","content_offset":["3725","3748"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-23%","3743","3747"],"indicator_element":{"时间":["2020年9月","3663","3670"],"产品":["人血白蛋白","3727","3732"],"渠道":["进口","3725","3727"]},"indicator_supplement":{"属性":""}}]},{"id":"59","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"占比68%","content_offset":["3749","3754"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["68%","3751","3754"],"indicator_element":{"时间":["2020年9月","3663","3670"],"产品":["人血白蛋白","3670","3675"],"渠道":["进口","3725","3727"]},"indicator_supplement":{"属性":""}}]},{"id":"60","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年9月，人血白蛋白批签发同比下降22%","content_offset":["4071","4094"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降22%","4089","4094"],"indicator_element":{"时间":["2020年9月","4071","4078"],"产品":["人血白蛋白","4079","4084"]},"indicator_supplement":{"属性":""}}]},{"id":"61","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"进口同比下降23%","content_offset":["4095","4104"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降23%","4099","4104"],"indicator_element":{"时间":["2020年9月","4071","4078"],"产品":["人血白蛋白","4079","4084"],"渠道":["进口","4095","4097"]},"indicator_supplement":{"属性":""}}]},{"id":"62","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"国产同比下降19%","content_offset":["4105","4114"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降19%","4109","4114"],"indicator_element":{"时间":["2020年9月","4071","4078"],"产品":["人血白蛋白","4079","4084"],"渠道":["国产","4105","4107"]},"indicator_supplement":{"属性":""}}]},{"id":"63","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"进口人血白蛋白批签发量2007年-2019年CAGR(年均复合增长率)为+34%","content_offset":["4221","4261"],"indicators":[{"indicator_name":"批签发量环比年复合增长率","indicator_value":["+34%","4257","4261"],"indicator_element":{"时间":["2007年-2019年","4232","4243"],"产品":["人血白蛋白","4223","4228"],"渠道":["进口","4221","4223"]},"indicator_supplement":{"属性":""}}]},{"id":"64","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年1-9月进口人血白蛋白批签发量为2887万瓶","content_offset":["4262","4289"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2887万瓶","4283","4289"],"indicator_element":{"时间":["2020年1-9月","4262","4271"],"产品":["人血白蛋白","4273","4278"],"渠道":["进口","4271","4273"]},"indicator_supplement":{"属性":""}}]},{"id":"65","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比增长29%","content_offset":["4290","4297"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["29%","4294","4297"],"indicator_element":{"时间":["2020年1-9月","4262","4271"],"产品":["人血白蛋白","4210","4215"],"渠道":["进口","4208","4210"]},"indicator_supplement":{"属性":""}}]},{"id":"66","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年9月进口人血白蛋白批签发量为346万瓶","content_offset":["4298","4322"],"indicators":[{"indicator_name":"批签发量","indicator_value":["346万瓶","4317","4322"],"indicator_element":{"时间":["2020年9月","4298","4305"],"产品":["人血白蛋白","4307","4312"],"渠道":["进口","4305","4307"]},"indicator_supplement":{"属性":""}}]},{"id":"67","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比下降23%","content_offset":["4097","4104"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降23%","4099","4104"],"indicator_element":{"时间":["2020年9月","4071","4078"],"产品":["人血白蛋白","4079","4084"],"渠道":["进口","4095","4097"]},"indicator_supplement":{"属性":""}}]},{"id":"68","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"国产人血白蛋白批签发量2007-2019年CAGR为+16%","content_offset":["5098","5128"],"indicators":[{"indicator_name":"批签发量","indicator_value":["+16%","5124","5128"],"indicator_element":{"时间":["2007-2019年","5109","5119"],"产品":["人血白蛋白","5100","5105"],"渠道":["国产","5098","5100"]},"indicator_supplement":{"属性":""}}]},{"id":"69","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年1-9月国产批签发量为1668万瓶","content_offset":["5145","5167"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1668万瓶","5161","5167"],"indicator_element":{"时间":["2020年1-9月","5145","5154"],"产品":["人血白蛋白","5100","5105"],"渠道":["国产","5154","5156"]},"indicator_supplement":{"属性":""}}]},{"id":"70","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比增长3%","content_offset":["5168","5174"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["3%","5172","5174"],"indicator_element":{"时间":["2020年1-9月","5145","5154"],"产品":["人血白蛋白","5100","5105"],"渠道":["国产","5098","5100"]},"indicator_supplement":{"属性":""}}]},{"id":"71","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年9月国产人血白蛋白批签发量为164万瓶，同比下降19%","content_offset":["5177","5209"],"indicators":[{"indicator_name":"批签发量","indicator_value":["164万瓶","5196","5201"],"indicator_element":{"时间":["2020年9月","5177","5184"],"产品":["人血白蛋白","5186","5191"],"渠道":["国产","5184","5186"]},"indicator_supplement":{"属性":""}}]},{"id":"72","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比下降19%","content_offset":["4107","4114"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降19%","4109","4114"],"indicator_element":{"时间":["2020年9月","4071","4078"],"产品":["人血白蛋白","4079","4084"],"渠道":["国产","4105","4107"]},"indicator_supplement":{"属性":""}}]},{"id":"73","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"静丙批签发量2007-2019年CAGR为+17%","content_offset":["6294","6319"],"indicators":[{"indicator_name":"批签发量环比年复合增长率","indicator_value":["+17%","6315","6319"],"indicator_element":{"时间":["2007-2019年","6300","6310"],"产品":["静丙","6294","6296"]},"indicator_supplement":{"属性":""}}]},{"id":"74","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年1-9月，静丙批签发总量为1004万瓶","content_offset":["6321","6345"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1004万瓶","6339","6345"],"indicator_element":{"时间":["2020年1-9月","6321","6330"]},"indicator_supplement":{"属性":""}}]},{"id":"75","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比增长11%","content_offset":["289","296"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["11%","293","296"],"indicator_element":{"时间":["2020年1-9月","253","262"]},"indicator_supplement":{"属性":""}}]},{"id":"76","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年9月静丙批签发量为89万瓶，","content_offset":["300","319"],"indicators":[{"indicator_name":"批签发量","indicator_value":["89万瓶","314","318"],"indicator_element":{"时间":["2020年9月","300","307"],"产品":["静丙","307","309"]},"indicator_supplement":{"属性":""}}]},{"id":"77","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比下降45%","content_offset":["319","326"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降45%","321","326"],"indicator_element":{"时间":["2020年9月","300","307"],"产品":["静丙","263","265"]},"indicator_supplement":{"属性":""}}]},{"id":"78","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年三季度静丙批签发量为290万瓶","content_offset":["6384","6404"],"indicators":[{"indicator_name":"批签发量","indicator_value":["290万瓶","6399","6404"],"indicator_element":{"时间":["2020年三季度","6384","6392"],"产品":["静丙","6392","6394"]},"indicator_supplement":{"属性":""}}]},{"id":"79","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比下降-34%","content_offset":["6405","6413"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-34%","6409","6413"],"indicator_element":{"时间":["2020年三季度","6384","6392"],"产品":["静丙","6331","6333"]},"indicator_supplement":{"属性":""}}]},{"id":"80","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"免疫球蛋白批签发量2008-2019复合增长率(CAGR)为+2%","content_offset":["7287","7320"],"indicators":[{"indicator_name":"批签发量环比年复合增长率","indicator_value":["+2%","7317","7320"],"indicator_element":{"时间":["2008-2019","7296","7305"],"产品":["免疫球蛋白","7287","7292"]},"indicator_supplement":{"属性":""}}]},{"id":"81","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年1-9月，免疫球蛋白批签发量为240万瓶","content_offset":["7352","7377"],"indicators":[{"indicator_name":"批签发量","indicator_value":["240万瓶","7372","7377"],"indicator_element":{"时间":["2020年1-9月","7352","7361"],"产品":["免疫球蛋白","7362","7367"]},"indicator_supplement":{"属性":""}}]},{"id":"82","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比增长110%","content_offset":["2251","2259"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["110%","2255","2259"],"indicator_element":{"时间":["2020年1-9月","2551","2560"],"产品":["免疫球蛋白","2241","2246"]},"indicator_supplement":{"属性":""}}]},{"id":"83","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年9月，免疫球蛋白批签发量为26万瓶","content_offset":["7387","7409"],"indicators":[{"indicator_name":"批签发量","indicator_value":["26万瓶","7405","7409"],"indicator_element":{"时间":["2020年9月","7387","7394"],"产品":["免疫球蛋白","7395","7400"]},"indicator_supplement":{"属性":""}}]},{"id":"84","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比上升56%","content_offset":["7410","7417"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["56%","7414","7417"],"indicator_element":{"时间":["2020年9月","7387","7394"],"产品":["免疫球蛋白","7321","7326"]},"indicator_supplement":{"属性":""}}]},{"id":"85","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年三季度，免疫球蛋白批签发量为55万瓶","content_offset":["7418","7441"],"indicators":[{"indicator_name":"批签发量","indicator_value":["55万瓶","7437","7441"],"indicator_element":{"时间":["2020年三季度","7418","7426"],"产品":["免疫球蛋白","7427","7432"]},"indicator_supplement":{"属性":""}}]},{"id":"86","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比下降16%","content_offset":["7442","7449"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降16%","7444","7449"],"indicator_element":{"时间":["2020年三季度","7418","7426"],"产品":["免疫球蛋白","7362","7367"]},"indicator_supplement":{"属性":""}}]},{"id":"87","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年1-9月狂犬病免疫球蛋白批签发总量为855万瓶","content_offset":["8568","8596"],"indicators":[{"indicator_name":"批签发量","indicator_value":["855万瓶","8591","8596"],"indicator_element":{"时间":["2020年1-9月","8568","8577"],"产品":["狂犬病免疫球蛋白","8577","8585"]},"indicator_supplement":{"属性":""}}]},{"id":"88","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比下降6%","content_offset":["2299","2305"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降6%","2301","2305"],"indicator_element":{"时间":["2020年1-9月","2551","2560"],"产品":["狂犬病免疫球蛋白","2286","2294"]},"indicator_supplement":{"属性":""}}]},{"id":"89","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年9月狂犬病免疫球蛋白批签发量为63万瓶","content_offset":["8604","8628"],"indicators":[{"indicator_name":"批签发量","indicator_value":["63万瓶","8624","8628"],"indicator_element":{"时间":["2020年9月","8604","8611"],"产品":["狂犬病免疫球蛋白","8611","8619"]},"indicator_supplement":{"属性":""}}]},{"id":"90","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比下降68%","content_offset":["8629","8636"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降68%","8631","8636"],"indicator_element":{"时间":["2020年9月","8604","8611"],"产品":["狂犬病免疫球蛋白","8577","8585"]},"indicator_supplement":{"属性":""}}]},{"id":"91","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年三季度狂犬病免疫球蛋白批签发量为263万瓶","content_offset":["8637","8663"],"indicators":[{"indicator_name":"批签发量","indicator_value":["263万瓶","8658","8663"],"indicator_element":{"时间":["2020年三季度","8637","8645"],"产品":["狂犬病免疫球蛋白","8645","8653"]},"indicator_supplement":{"属性":""}}]},{"id":"92","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比下降41%","content_offset":["8664","8671"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降41%","8666","8671"],"indicator_element":{"时间":["2020年三季度","8637","8645"],"产品":["狂犬病免疫球蛋白","8577","8585"]},"indicator_supplement":{"属性":""}}]},{"id":"93","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"破伤风免疫球蛋白批签发量2008-2019年复合年均增长率(CAGR)为+12%","content_offset":["9709","9749"],"indicators":[{"indicator_name":"批签发量环比年复合增长率","indicator_value":["+12%","9745","9749"],"indicator_element":{"时间":["2008-2019年","9721","9731"],"产品":["破伤风免疫球蛋白","9709","9717"]},"indicator_supplement":{"属性":""}}]},{"id":"94","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年1-9月，破伤风免疫球蛋白批签发总量为411万瓶","content_offset":["9779","9808"],"indicators":[{"indicator_name":"批签发量","indicator_value":["411万瓶","9803","9808"],"indicator_element":{"时间":["2020年1-9月","9779","9788"],"产品":["破伤风免疫球蛋白","9789","9797"]},"indicator_supplement":{"属性":""}}]},{"id":"95","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比下降17%","content_offset":["2342","2349"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降17%","2344","2349"],"indicator_element":{"时间":["2020年1-9月","2551","2560"],"产品":["破伤风免疫球蛋白","2329","2337"]},"indicator_supplement":{"属性":""}}]},{"id":"96","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年9月份，破伤风免疫球蛋白批签发量为22万瓶","content_offset":["9817","9843"],"indicators":[{"indicator_name":"批签发量","indicator_value":["22万瓶","9839","9843"],"indicator_element":{"时间":["2020年9月份","9817","9825"],"产品":["破伤风免疫球蛋白","9826","9834"]},"indicator_supplement":{"属性":""}}]},{"id":"97","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比下降72%","content_offset":["9844","9851"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降72%","9846","9851"],"indicator_element":{"时间":["2020年9月份","9817","9825"],"产品":["破伤风免疫球蛋白","9754","9762"]},"indicator_supplement":{"属性":""}}]},{"id":"98","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年三季度，破伤风免疫球蛋白批签发量为106万瓶","content_offset":["9852","9879"],"indicators":[{"indicator_name":"批签发量","indicator_value":["106万瓶","9874","9879"],"indicator_element":{"时间":["2020年三季度","9852","9860"],"产品":["破伤风免疫球蛋白","9861","9869"]},"indicator_supplement":{"属性":""}}]},{"id":"99","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比下降54%","content_offset":["9880","9887"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降54%","9882","9887"],"indicator_element":{"时间":["2020年三季度","9852","9860"],"产品":["破伤风免疫球蛋白","9789","9797"]},"indicator_supplement":{"属性":""}}]},{"id":"100","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年1-9月，破伤风免疫球蛋白批签发总量为428万瓶","content_offset":["10205","10234"],"indicators":[{"indicator_name":"批签发量","indicator_value":["428万瓶","10229","10234"],"indicator_element":{"时间":["2020年1-9月","10205","10214"],"产品":["破伤风免疫球蛋白","10215","10223"]},"indicator_supplement":{"属性":""}}]},{"id":"101","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比下降13%","content_offset":["10235","10242"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降13%","10237","10242"],"indicator_element":{"时间":["2020年1-9月","10205","10214"],"产品":["破伤风免疫球蛋白","10135","10143"]},"indicator_supplement":{"属性":""}}]},{"id":"102","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年9月份，破伤风免疫球蛋白批签发量为签发量为39万瓶","content_offset":["10243","10273"],"indicators":[{"indicator_name":"批签发量","indicator_value":["39万瓶","10269","10273"],"indicator_element":{"时间":["2020年9月份","10243","10251"],"产品":["破伤风免疫球蛋白","10252","10260"]},"indicator_supplement":{"属性":""}}]},{"id":"103","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比下降52%","content_offset":["10019","10026"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降52%","10021","10026"],"indicator_element":{"时间":["2020年9月份","10243","10251"],"产品":["破伤风免疫球蛋白","10036","10044"]},"indicator_supplement":{"属性":""}}]},{"id":"104","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"乙肝免疫球蛋白2007-2019复合增长率(CAGR)为-1%","content_offset":["10972","11003"],"indicators":[{"indicator_name":"批签发量环比年复合增长率","indicator_value":["-1%","11000","11003"],"indicator_element":{"时间":["2007-2019年","-1","-1"],"产品":["乙肝免疫球蛋白","10972","10979"]},"indicator_supplement":{"属性":""}}]},{"id":"105","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年1-9月，乙肝免疫球蛋白批签发总量为135万瓶","content_offset":["11005","11033"],"indicators":[{"indicator_name":"批签发量","indicator_value":["135万瓶","11028","11033"],"indicator_element":{"时间":["2020年1-9月","11005","11014"],"产品":["乙肝免疫球蛋白","11015","11022"]},"indicator_supplement":{"属性":""}}]},{"id":"106","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比上升7%","content_offset":["11034","11040"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["7%","11038","11040"],"indicator_element":{"时间":["2020年1-9月","11005","11014"],"产品":["乙肝免疫球蛋白","10953","10960"]},"indicator_supplement":{"属性":""}}]},{"id":"107","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年9月份，乙肝免疫球蛋白批签发量为36万瓶，同比增长257%","content_offset":["11041","11075"],"indicators":[{"indicator_name":"批签发量","indicator_value":["36万瓶","11062","11066"],"indicator_element":{"时间":["2020年9月份","11041","11049"],"产品":["乙肝免疫球蛋白","11050","11057"]},"indicator_supplement":{"属性":""}}]},{"id":"108","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比增长257%","content_offset":["11067","11075"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["257%","11071","11075"],"indicator_element":{"时间":["2020年9月份","11041","11049"],"产品":["乙肝免疫球蛋白","10972","10979"]},"indicator_supplement":{"属性":""}}]},{"id":"109","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年三季度，乙肝免疫球蛋白批签发量为63万瓶","content_offset":["11076","11101"],"indicators":[{"indicator_name":"批签发量","indicator_value":["63万瓶","11097","11101"],"indicator_element":{"时间":["2020年三季度","11076","11084"],"产品":["乙肝免疫球蛋白","11085","11092"]},"indicator_supplement":{"属性":""}}]},{"id":"110","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比增长245%","content_offset":["11102","11110"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["245%","11106","11110"],"indicator_element":{"时间":["2020年三季度","11076","11084"],"产品":["乙肝免疫球蛋白","11015","11022"]},"indicator_supplement":{"属性":""}}]},{"id":"111","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"凝血酶原复合物批签发2008-2019年CAGR为+28%","content_offset":["12032","12061"],"indicators":[{"indicator_name":"批签发量环比年复合增长率","indicator_value":["+28%","12057","12061"],"indicator_element":{"时间":["2008-2019年","12042","12052"],"产品":["凝血酶原复合物","12032","12039"]},"indicator_supplement":{"属性":""}}]},{"id":"112","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年1-9月，凝血酶原复合物批签发总量为113万瓶","content_offset":["12129","12157"],"indicators":[{"indicator_name":"批签发量","indicator_value":["113万瓶","12152","12157"],"indicator_element":{"时间":["2020年1-9月","12129","12138"],"产品":["凝血酶原复合物","12139","12146"]},"indicator_supplement":{"属性":""}}]},{"id":"113","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比增长43%","content_offset":["2425","2432"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["43%","2429","2432"],"indicator_element":{"时间":["2020年1-9月","2551","2560"],"产品":["凝血酶原复合物","2413","2420"]},"indicator_supplement":{"属性":""}}]},{"id":"114","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年9月，凝血酶原复合物批签发量为16万瓶","content_offset":["12166","12190"],"indicators":[{"indicator_name":"批签发量","indicator_value":["16万瓶","12186","12190"],"indicator_element":{"时间":["2020年9月","12166","12173"],"产品":["凝血酶原复合物","12174","12181"]},"indicator_supplement":{"属性":""}}]},{"id":"115","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比上升112%","content_offset":["12191","12199"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["112%","12195","12199"],"indicator_element":{"时间":["2020年9月","12166","12173"],"产品":["凝血酶原复合物","12139","12146"]},"indicator_supplement":{"属性":""}}]},{"id":"116","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年三季度，凝血酶原复合物批签发量为33万瓶","content_offset":["12200","12225"],"indicators":[{"indicator_name":"批签发量","indicator_value":["33万瓶","12221","12225"],"indicator_element":{"时间":["2020年三季度","12200","12208"],"产品":["凝血酶原复合物","12209","12216"]},"indicator_supplement":{"属性":""}}]},{"id":"117","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比下降20%","content_offset":["12226","12233"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降20%","12228","12233"],"indicator_element":{"时间":["2020年三季度","12200","12208"],"产品":["凝血酶原复合物","12139","12146"]},"indicator_supplement":{"属性":""}}]},{"id":"118","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"凝血因子VIII行业2008-2019年CAGR为-2%","content_offset":["13011","13039"],"indicators":[{"indicator_name":"批签发量环比年复合增长率","indicator_value":["-2%","13036","13039"],"indicator_element":{"时间":["2008-2019年","13021","13031"],"产品":["凝血因子VIII","13011","13019"]},"indicator_supplement":{"属性":""}}]},{"id":"119","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年1-9月，凝血因子Ⅷ批签发总量为166万瓶","content_offset":["13058","13084"],"indicators":[{"indicator_name":"批签发量","indicator_value":["166万瓶","13079","13084"],"indicator_element":{"时间":["2020年1-9月","13058","13067"],"产品":["凝血因子VIII","13011","13019"]},"indicator_supplement":{"属性":""}}]},{"id":"120","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比增长27%","content_offset":["13085","13092"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["27%","13089","13092"],"indicator_element":{"时间":["2020年1-9月","13058","13067"],"产品":["凝血因子VIII","13011","13019"]},"indicator_supplement":{"属性":""}}]},{"id":"121","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年9月，凝血因子Ⅷ批签发量为22万瓶","content_offset":["13093","13115"],"indicators":[{"indicator_name":"批签发量","indicator_value":["22万瓶","13111","13115"],"indicator_element":{"时间":["2020年9月","13093","13100"],"产品":["凝血因子VIII","13011","13019"]},"indicator_supplement":{"属性":""}}]},{"id":"122","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比上升41%","content_offset":["13116","13123"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["41%","13120","13123"],"indicator_element":{"时间":["2020年9月","13093","13100"],"产品":["凝血因子VIII","13306","13314"]},"indicator_supplement":{"属性":""}}]},{"id":"123","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年三季度，凝血因子Ⅷ批签发量为65万瓶","content_offset":["13124","13147"],"indicators":[{"indicator_name":"批签发量","indicator_value":["65万瓶","13143","13147"],"indicator_element":{"时间":["2020年三季度","13124","13132"],"产品":["凝血因子VIII","13306","13314"]},"indicator_supplement":{"属性":""}}]},{"id":"124","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比上升11%","content_offset":["13148","13155"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["11%","13152","13155"],"indicator_element":{"时间":["2020年三季度","13124","13132"],"产品":["凝血因子VIII","13306","13314"]},"indicator_supplement":{"属性":""}}]},{"id":"125","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"纤维蛋白原2008-2019年CAGR为+49%","content_offset":["14035","14059"],"indicators":[{"indicator_name":"批签发量环比年复合增长率","indicator_value":["+49%","14055","14059"],"indicator_element":{"时间":["2008-2019年","14040","14050"],"产品":["纤维蛋白原","14035","14040"]},"indicator_supplement":{"属性":""}}]},{"id":"126","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年1-9月，纤维蛋白原批签发总量为82万瓶","content_offset":["14078","14103"],"indicators":[{"indicator_name":"批签发量","indicator_value":["82万瓶","14099","14103"],"indicator_element":{"时间":["2020年1-9月","14078","14087"],"产品":["纤维蛋白原","14088","14093"]},"indicator_supplement":{"属性":""}}]},{"id":"127","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比增长17%","content_offset":["14104","14111"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["17%","14108","14111"],"indicator_element":{"时间":["2020年1-9月","14078","14087"],"产品":["纤维蛋白原","14024","14029"]},"indicator_supplement":{"属性":""}}]},{"id":"128","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年9月，纤维蛋白原批签发量为6万瓶","content_offset":["14112","14133"],"indicators":[{"indicator_name":"批签发量","indicator_value":["6万瓶","14130","14133"],"indicator_element":{"时间":["2020年9月","14112","14119"],"产品":["纤维蛋白原","14120","14125"]},"indicator_supplement":{"属性":""}}]},{"id":"129","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比增长20%","content_offset":["14134","14141"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["20%","14138","14141"],"indicator_element":{"时间":["2020年9月","14112","14119"],"产品":["纤维蛋白原","14035","14040"]},"indicator_supplement":{"属性":""}}]},{"id":"130","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年三季度，纤维蛋白原批签发量为19万瓶","content_offset":["14142","14165"],"indicators":[{"indicator_name":"批签发量","indicator_value":["19万瓶","14161","14165"],"indicator_element":{"时间":["2020年三季度","14142","14150"],"产品":["纤维蛋白原","14151","14156"]},"indicator_supplement":{"属性":""}}]},{"id":"131","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"同比下降22%","content_offset":["4087","4094"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降22%","4089","4094"],"indicator_element":{"时间":["2020年三季度","6384","6392"],"产品":["纤维蛋白原","13983","13988"]},"indicator_supplement":{"属性":""}}]},{"id":"132","source_document":"2020年1-9月血制品批签发：Q3多数品种出现不同程度下滑.pdf","content":"2020年9月共8种产品获批，其中PCC获批7万瓶(+57%)，凝血因子Ⅷ获批5万瓶(+46%)，乙免获批10万瓶，去年同期无批签发，破免获批5万瓶(-82%)，狂免获批10万瓶(-72%)，静丙获批14万瓶(-22%)，人白获批26万瓶(-11%)，乙免获批10万瓶，去年同期无批签发","content_offset":["-1","-1"],"indicators":[{"indicator_name":"获批数量","indicator_value":["7万瓶","21","24"],"indicator_element":{"产品":["PCC","16","19"],"时间":["2020年9月","-1","6"]},"indicator_supplement":{"属性":""}},{"indicator_name":"获批数量","indicator_value":["5万瓶","38","41"],"indicator_element":{"产品":["凝血因子Ⅷ","31","36"],"时间":["2020年9月","-1","6"]},"indicator_supplement":{"属性":""}},{"indicator_name":"获批数量","indicator_value":["10万瓶","52","56"],"indicator_element":{"产品":["乙免","48","50"],"时间":["2020年9月","-1","6"]},"indicator_supplement":{"属性":""}},{"indicator_name":"获批数量","indicator_value":["5万瓶","38","41"],"indicator_element":{"产品":["破免","66","68"],"时间":["2020年9月","-1","6"]},"indicator_supplement":{"属性":""}},{"indicator_name":"获批数量","indicator_value":["10万瓶","52","56"],"indicator_element":{"产品":["狂免","80","82"],"时间":["2020年9月","-1","6"]},"indicator_supplement":{"属性":""}},{"indicator_name":"获批数量","indicator_value":["14万瓶","99","103"],"indicator_element":{"产品":["静丙","95","97"],"时间":["2020年9月","-1","6"]},"indicator_supplement":{"属性":""}},{"indicator_name":"获批数量","indicator_value":["26万瓶","114","118"],"indicator_element":{"产品":["人白","110","112"],"时间":["2020年9月","-1","6"]},"indicator_supplement":{"属性":""}},{"indicator_name":"获批数量","indicator_value":["10万瓶","52","56"],"indicator_element":{"产品":["乙免","48","50"],"时间":["2020年9月","-1","6"]},"indicator_supplement":{"属性":""}}]}]}